Febit, Inc. Launches New Instrument for Targeted NextGen Sequencing With High Sample Throughput at AGBT Conference  
2/17/2010 9:54:44 AM

Bookmark and Share

LEXINGTON, Mass. and HEIDELBERG, Germany, Feb. 17 /PRNewswire/ -- febit today announced the launch of its HybSelector, a new instrument for high throughput targeted resequencing, at the 11th annual Advances in Genome Biology and Technology (AGBT) meeting on February 24-27, 2010, in Marco Island, Florida. AGBT is now widely regarded as the premier scientific forum for sharing information about the latest advances in new DNA sequencing technologies and their application to diverse areas in biology and biomedical research.

The new HybSelector instrument will replace the Geniom RT Analyzer for high-quality DNA enrichment followed by targeted next-generation sequencing. The compact HybSelector combines febit's well established expertise in the development and manufacture of technologies for genome exploration with the most advanced high-quality DNA enrichment automation available on the market.

"The HybSelector features all technical components necessary for HybSelect, our DNA enrichment protocol," said Peer Staehler, CSO at febit. "We are able to offer the HybSelector at a very competitive price. This will enable the large genomics research community, which has already indicated a high interest in affordable targeted re-sequencing solutions, to use HybSelect's high sample throughput at low acquisition costs."

The economic benefit of HybSelect increases the potential for widespread use of next generation sequencing in clinical studies. Instead of sequencing the complete genomes of only a limited number of patients, HybSelect enables the analysis of specific genes of interest from large patient cohorts for the same price and data management effort. The larger patient pool now provides the statistically relevant data that are necessary for clinical studies.

About febit

febit develops, produces and markets flexible automated solutions for enabling biochip applications in Life Sciences. febit's product portfolio includes various instruments, optimized assays and bioanalytical services, complemented by bioinformatics software and consulting.

The key applications are HybSelect, febit's innovative DNA capture method for Next-Generation-Sequencing, and hands-off, amplification free microRNA profiling. Both are taking advantage of the advanced microfluidics of the patented Geniom Biochip to offer the highest degree of automation, flexibility and efficiency available.

For more information, please visit

Contact: febit group, Eva Sterzel,, +49 (0)6221 6510-300 Russo Partners, Martina Schwarzkopf,, +1 212 845-4292 SOURCE febit